Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06553352
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-11
Brief Title:
Zanubrutinib in Combination With Obinutuzumab ZO for Newly Diagnosed Follicular Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open Single-Arm Clinical Study of Zanubrutinib in Combination With Obinutuzumab ZO for Newly Diagnosed Follicular Lymphoma FL
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab ZO in the treatment of newly diagnosed follicular lymphoma
Detailed Description:
Zanubrutinib Z 160mg bid oral d1-21 Obinutuzumab O C1 1000mg d1815 C2-C6 d1 IV then every 8 weeks until full 20 infusions 1 year maintenance
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None